Climb Bio Reports Early Phase 2 Budoprutug Data in pMN

Initial Phase 2 data showed B-cell depletion, reduced PLA2R antibodies and immunologic remission at 12 weeks with 200 mg budoprutug. Early 600 mg data suggested greater exposure and deeper depletion; both doses were generally well tolerated through Week 12 and Week 6, respectively.